QC
CMPX icon

Quadrature Capital’s Compass Therapeutics CMPX Stock Holding History

Quadrature Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
108,250
+94,405
+682% +$279K ﹤0.01% 1297
2026
Q1 		$73.2K Buy
13,845
+1,552
+13% +$8.96K ﹤0.01% 1260
2025
Q4 		$66K Sell
12,293
-35,134
-74% -$162K ﹤0.01% 1146
2025
Q3 		$166K Buy
+47,427
New +$150K ﹤0.01% 812

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrature Capital's CMPX Position: Q2 2026 in Review

Quadrature Capital increased its Compass Therapeutics (CMPX) stake by 682% in Q2 2026, buying an estimated $279K and bringing the position to 108,250 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

Quadrature Capital first reported a position in CMPX in Q3 2025 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Quadrature Capital held 108,250 shares of Compass Therapeutics worth $237K as of Q2 2026.
  • Quadrature Capital bought 94,405 Compass Therapeutics shares in Q2 2026, an estimated $279K.
  • Compass Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1297 holding.
  • Quadrature Capital first reported a position in Compass Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.